Dacarbazine + Doxorubicin Hydrochloride + Pembrolizumab + Vinblastine Sulfate

Phase 2UNKNOWN

0 views this week 0 watching💤 Quiet

Interest: 31/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Classical Hodgkin Lymphoma

Conditions

Classical Hodgkin Lymphoma, Lymphocyte-Depleted Classical Hodgkin Lymphoma, Lymphocyte-Rich Classical Hodgkin Lymphoma, Mixed Cellularity Classical Hodgkin Lymphoma, Nodular Sclerosis Classical Hodgkin Lymphoma

Trial Timeline

Nov 9, 2017 → Oct 1, 2024

NCT ID

NCT03226249

About Dacarbazine + Doxorubicin Hydrochloride + Pembrolizumab + Vinblastine Sulfate

Dacarbazine + Doxorubicin Hydrochloride + Pembrolizumab + Vinblastine Sulfate is a phase 2 stage product being developed by Merck for Classical Hodgkin Lymphoma. The current trial status is unknown. This product is registered under clinical trial identifier NCT03226249. Target conditions include Classical Hodgkin Lymphoma, Lymphocyte-Depleted Classical Hodgkin Lymphoma, Lymphocyte-Rich Classical Hodgkin Lymphoma.

What happened to similar drugs?

0 of 2 similar drugs in Classical Hodgkin Lymphoma were approved

Approved (0) Terminated (1) Active (1)

🔄Camrelizumab + Investigator's choice of ChemotherapyJiangsu Hengrui MedicinePhase 3

❌Tislelizumab + Salvage ChemotherapyBeOne MedicinesPhase 3

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (1)

NCT ID	Phase	Status	Start	Completion	Indication
NCT03226249	Phase 2	UNKNOWN	Nov 9, 2017	Oct 1, 2024	Classical Hodgkin Lymphoma

Competing Products

11 competing products in Classical Hodgkin Lymphoma

See all competitors

Product	Company	Stage	Hype Score
Camrelizumab + Investigator's choice of Chemotherapy	Jiangsu Hengrui Medicine	Phase 3	36
Sabestomig (AZD7789)	AstraZeneca	Phase 1	29
Pembrolizumab + Doxorubicin + Vinblastine + Dacarbazine + Brentuximab vedotin	Merck	Phase 2	42
Pembrolizumab + Doxorubicin + Vinblastine + Dacarbazine + Bleomycin + Etoposide + Cyclophosphamide + Vincristine + Procarbazine + Prednisone	Merck	Phase 2	35
Carboplatin + Etoposide + Ifosfamide + Pembrolizumab	Merck	Phase 2	31
Pembrolizumab (+) Berahyaluronidase alfa	Merck	Phase 2	39
Panobinostat	Novartis	Phase 2	35
PD1	Innovent Biologics	Phase 2	35
Nivolumab + Autologous CD30.CAR-T + Fludarabine + Bendamustine	Bristol Myers Squibb	Phase 1	33
Tislelizumab + Salvage Chemotherapy	BeOne Medicines	Phase 3	29
GEN3017	Genmab	Phase 1/2	21